Company Overview
| Stock Name | Chinares Pharma |
|---|---|
| Stock Code | 03320 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國領先的綜合醫藥公司,從事研發、製造、分銷及零售種類繁多的醫藥及其他營養保健品,主要經營製藥、醫藥分銷及藥品零售三大分部。 |
| Listing Date | 2016-10-28 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 香港灣仔港灣道26號華潤大廈41樓4104-05室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.crpharm.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 9.10 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2016-10-17 to 2016-10-20 |
| Global Offering Shares | 1,543,141,500 shares |
| HK Public Offer Shares (Initial) | 77,158,000 shares (5.0%) |
| Public Offer Lots (Initial) | 154,316lots (Pool A77,158lots,Pool B77,158lots) |
| International Placing Shares (Initial) | 1,465,983,500 shares (95.0%) |
| Offer Ratio | ~5.0% |
| Total Shares Post-IPO | 6,172,565,961 shares |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 12.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 14,042,587,650 |
Stock Connect Inclusion Analysis
| Avg Daily HK Mkt Cap | HK$ 29.66B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約港幣6,082.2百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | ~HK$ 377,100,000 |
| Listing Expenses / Funds Raised | ~2.69% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
HKD
Income Statement
| Item | 2013 | 2014 | 2015 | 2016-06 |
|---|---|---|---|---|
| Revenue | 116,950,696 | 135,749,180 | 146,568,105 | 75,615,523 |
| Cost of sales | -96,801,611 | -114,259,158 | -123,369,243 | -63,862,413 |
| Gross profit | 20,149,085 | 21,490,022 | 23,198,862 | 11,753,110 |
| Other income and gains, net | 756,322 | 917,521 | 1,002,378 | 451,866 |
| Selling and distribution expenses | -8,423,115 | -8,800,154 | -10,111,546 | -4,968,248 |
| Administrative expenses | -3,673,505 | -4,246,773 | -3,844,892 | -1,743,811 |
| Operating profit | 8,683,647 | 9,057,372 | 10,100,757 | 5,117,870 |
| Net finance costs | -1,770,734 | -2,134,599 | -2,050,462 | -889,096 |
| Share of associates and JVs | 49,054 | 64,640 | 58,224 | 31,832 |
| Profit before tax | 6,912,913 | 6,922,773 | 8,050,295 | 4,228,774 |
| Income tax expense | -1,458,286 | -1,430,902 | -1,968,061 | -1,048,264 |
| Profit for the year | 5,454,627 | 5,491,871 | 6,082,234 | 3,180,510 |
| Profit attributable to owners | 2,639,517 | 2,645,940 | 2,850,076 | 1,636,069 |
Balance Sheet
| Item | 2013 | 2014 | 2015 | 2016-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 15,175,387 | 13,417,624 | 12,378,606 | 10,475,006 |
| Trade and bills receivables | 38,044,588 | 45,189,028 | 47,514,249 | 53,428,379 |
| Inventories | 12,198,122 | 15,711,480 | 15,251,983 | 16,206,052 |
| Total current assets | 68,797,831 | 84,277,191 | 88,856,877 | 87,986,880 |
| Total assets | 104,823,067 | 121,797,602 | 127,148,599 | 125,916,533 |
| Total current liabilities | 58,897,907 | 65,472,488 | 72,223,796 | 71,190,338 |
| Total liabilities | 72,174,373 | 84,647,148 | 87,303,034 | 86,214,140 |
| Total equity | 32,648,694 | 37,150,454 | 39,845,565 | 39,702,393 |
| Equity attributable to owners | 17,988,255 | 20,516,319 | 22,502,235 | 22,597,665 |
| Interest-bearing borrowings | 31,215,597 | 37,262,846 | 37,218,338 | 37,728,447 |
Cash Flow Statement
| Item | 2013 | 2014 | 2015 | 2016-06 |
|---|---|---|---|---|
| Net cash from operating activities | 4,102,157 | 4,186,722 | 5,988,790 | 611,572 |
| Net cash from investing activities | -5,788,721 | -7,979,088 | -3,919,222 | -426,924 |
| Net cash from financing activities | 4,008,669 | 3,090,312 | -1,554,283 | -2,527,495 |
| Net increase in cash | 2,322,105 | -702,054 | 515,285 | -2,342,847 |
| Depreciation of PP&E | 942,421 | 1,048,000 | 1,090,257 | 564,676 |
| Amortisation of intangible assets | 191,316 | 228,601 | 198,358 | 110,635 |
| Purchase of PP&E | -2,264,144 | -2,015,446 | -1,246,284 | -473,531 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 9.01 |
|---|---|
| First Day Open | HK$ 9.1 |
| First Day Change | -0.99% |
| First Day Volume | 119767000.0 |
| First Day Turnover | 1081380000.0 |
| Use of Proceeds | 1、約45%的所得款項凈額或約港幣6,288.4百萬元預期用作戰略收購,擴大制藥及醫藥分銷業務;
2、約15%的所得款項凈額或約港幣2,096.1百萬元預期用作在中國建立更多的醫藥分銷業務的先進物流中心及倉庫;
3、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作投資于研發平臺;
4、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作改進及升級我們的信息技術系統;
5、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作償還由華潤醫藥控股發行的部分未償還債券;
6、約10%的所得款項凈額或約港幣1,397.4百萬元預期用作營運資金及一般公司用途。 |
Underwriting Syndicate
Joint Sponsors (4)
Overall Coordinators (5)
Joint Bookrunners (14)
中国国际金融香港证券有限公司 CE AEN894
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Merrill Lynch (Asia Pacific) Limited CE AAC198
建银国际金融有限公司 CE AJO225
Morgan Stanley Asia Limited CE AAD291
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
ICBC INTERNATIONAL CAPITAL LIMITED CE AQW615
香港上海汇丰银行有限公司 CE AAA523
MIZUHO SECURITIES ASIA LIMITED CE AEZ953
中信建投(国际)融资有限公司 CE BAU112
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
农银国际融资有限公司 CE AWL249
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Joint Lead Managers (14)
中国国际金融香港证券有限公司 CE AEN894
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536
Merrill Lynch (Asia Pacific) Limited CE AAC198
建银国际金融有限公司 CE AJO225
Morgan Stanley Asia Limited CE AAD291
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299
香港上海汇丰银行有限公司 CE AAA523
MIZUHO SECURITIES ASIA LIMITED CE AEZ953
中信建投(国际)融资有限公司 CE BAU112
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
农银国际证券有限公司 CE ACX411
J.P. Morgan Securities (Asia Pacific) Limited CE AAJ321
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | High Action Limited | 233,997,400 HKD | — | 0.42% | — | 6 months | 2017-04-28 |
| 2 | London International Trading (Asia) Limited | 387,905,700 HKD | — | 0.69% | — | 6 months | 2017-04-28 |
| 3 | Nordea Investment Management AB | 699,999,300 HKD | — | 1.25% | — | 6 months | 2017-04-28 |
| 4 | 安邦投资控股有限公司 | 379,433,600 HKD | — | 0.68% | — | 6 months | 2017-04-28 |
| 5 | 富士胶片公司 | 819,996,450 HKD | — | 1.46% | — | 6 months | 2017-04-28 |
| 6 | 恒健国际投资控股(香港)有限公司 | 2,637,953,500 HKD | — | 4.70% | — | 6 months | 2017-04-28 |
| 7 | 中国诚通控股集团有限公司 | 387,933,000 HKD | — | 0.69% | — | 6 months | 2017-04-28 |
| 8 | 中国人寿保险(集团)公司 | 1,551,732,000 HKD | — | 2.76% | — | 6 months | 2017-04-28 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 白曉松 | — |
| Company Secretary | 溫詠宜 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 華潤集團(醫藥)直接持有54.00%,北京醫藥投資直接持有17.74%,北京國管中心合計持有21.00%(假設超額配股權並無獲行使)。 |
|---|




